Evommune shares are trading lower after the company announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. The experimental drug failed to reach both its primary and secondary endpoints across all tested dose levels, and the firm decided that it would not move EVO756 forward for atopic dermatitis.